View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Theme
  2. Macro
  3. Covid-19
June 9, 2020

AstraZeneca licences Covid-19 antibody candidates from VU

AstraZeneca has licensed six coronavirus-neutralising antibody candidates from Vanderbilt University (VU) in the US, with plans to advance two into clinical development to prevent and treat Covid-19.

The company has assessed the ability of more than 1,500 monoclonal antibodies (mAbs) to attach to the SARS-CoV-2 virus and block it from infecting healthy cells in a laboratory setting.

Based on these pre-clinical findings, the company has entered an exclusive licence agreement for six antibody candidate currently in VU’s portfolio that targets the novel coronavirus.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology